Breakthrough in Device Therapy for Patients with Late Stage Heart Disease

Calon Cardio-Technology Ltd. and Leviticus-Cardio Ltd. announce the joint Development and Testing of a Wireless, Fully Implantable, Long-Term Blood Pump.

Breakthrough in Device Therapy – Late Stage Heart Disease: Severe heart failure is the most life-threatening medical condition in all age groups across the globe. Implantable heart pumps, known as Ventricular Assist Devices (or VADs), have proven to sustainably increase long term survival. However, due to the need for tethering to an external power source using a cable exiting the body through the abdomen, these devices have not yet been fully accepted as mainstream therapy.

Now, for the first time globally, a compact, fully implantable VAD (FiVAD) has been successfully implemented by combining the Calon Cardio MiniVAD™ with the versatile, fully implantable wireless energy recharging system of Leviticus Cardio. Completion of a 60-day in-vivo pre-clinical study of this FiVAD has successfully validated the integration of these two innovative technologies.

This new disruptive technology, FiVAD, will allow a patient a full day without a cable or connection to any external equipment whatsoever. The recharging process itself only requires a light belt around the patient’s chest during the night. The successful elimination of the electric power cable is a major step forward leading to a near-normal quality of life for these severely ill patients. It will convince physicians around the world that VAD therapy has reached the point of routine use and will lead to widespread application of this life saving therapy.

The trial was conducted at the internationally recognized Centre of Excellence at the Catholic University of Leuven, in Belgium. The success of this ground-breaking study marks a further step in the integration of the two companies that are committed to taking this life-changing innovation in partnership to patients across the globe.

Stuart McConchie, CEO of Calon Cardio-Technology Ltd: “The combination of our MiniVAD, designed to optimize blood handling, and the Leviticus wireless technology provides a safe and usable truly wireless VAD system, representing major progress in blood pump technology. Together this FiVAD will significantly improve the lives of vast numbers of late-stage heart failure patients.”

Michael Zilbershlag, CEO of Leviticus Cardio Ltd: “Our study has demonstrated that the combination of the very effective Calon MiniVAD™ and the Leviticus FiVAD offers for the first time a fully functioning heart pump without the need to be recharged for more than 10 hours allowing freedom from any external equipment for a whole working day.”

Marc Clement, Chairman of Calon Cardio-Technology Ltd: “I am sure I speak for both companies when I say how delighted we are with the outcome of the integration of our respective ground-breaking technologies. We are committed to a long-term relationship that will improve the quality of life of thousands of patients across the world.”

“The successful 60-days preclinical milestone of the MiniVAD and FiVAD platform poses an encouraging accomplishment in further integration of these two innovative technologies,” states Professor Ivan Netuka, Cardiac Surgeon, a Chairman in the Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.

Professor Stephen Westaby, renowned heart surgeon (now retired) and a founder of Calon Cardio impresses that “The critical importance of the integration of the Calon Cardio and Leviticus Cardio technologies is the elimination of driveline infection. Infection destroys quality of life, promotes thrombosis and stroke, and too often results in substantial early mortality. The integrated FiVAD is a system that has the potential to supersede cardiac transplant as the preferred intervention in advanced heart failure, without needing someone else to die first.”

“A system like this will give patients the freedom to do what they like for more than a whole working day without any external cable connections. When in clinical practice, this is more than we as physicians could have ever dreamed for VAD patient quality of life,” adds Professor Stephan Schueler, Head of Department of Cardiothoracic Surgery at The Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy